Release Date: February 19, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you provide more details on the expected growth rate for 2025, particularly the difference between the first and second halves of the year? A: Mehul Joshi, Chief Financial Officer, explained that while they do not provide specific guidance for the first versus the second half, they expect strong international growth in the first half due to initiatives from 2024. In the U.S., growth is expected to accelerate in the second half as pilot initiatives are fully implemented.
Q: What feedback have you received from the Lung Tracks pilot, and how is it impacting utilization at centers? A: Steven Williamson, President and CEO, noted that customers appreciate the ability to passively find new patients. The integration and interface have been positively received, and initial data aligns with expectations. The pilot's success has led to plans for broader rollout in the second quarter.
Q: Can you elaborate on the significant international growth in Q4 and whether it included any one-time orders? A: Mehul Joshi stated that the growth was broad-based across European and Chinese markets, with no significant one-time stocking orders. The growth was driven by recurring business and strategic initiatives in these regions.
Q: Why is the 2025 growth guidance below the long-term target of 20%, and when do you expect to reach that target? A: Steven Williamson explained that the 17% midpoint guidance for 2025 is conservative, considering the time needed to implement new initiatives. They expect growth to accelerate in the latter half of 2025 and continue into 2026 with additional drivers like the Japanese post-approval study and Aeroseal launch.
Q: How are you measuring the effectiveness of your investments in new centers, salespeople, and direct-to-consumer campaigns? A: Steven Williamson mentioned that they track patient acquisition through their website and measure the efficiency of therapy awareness specialists by the number of referrals from COPD community physicians. They continuously assess these metrics to ensure effective investment.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.